UPS Completes Acquisitions of Healthcare Cold-Chain Logistics Providers Frigo-Trans and BPL
Acquisitions Accelerate Plan to Provide Healthcare Customers with End-to-End Temperature-Controlled Solutions Across Europe
UPS (NYSE: UPS) today announced that it has completed the acquisition of Frigo-Trans and its sister company BPL, which provide industry-leading, complex healthcare logistics solutions across Europe.
The acquisitions further enhance the end-to-end capabilities available to UPS Healthcare customers, who increasingly need temperature-controlled and time-critical logistics solutions globally. Frigo-Trans’ network includes temperature-controlled warehousing ranging from cryopreservation (-196°C) to ambient (+15° to +25°C) as well as Pan-European cold chain transportation. This combined with the logistics solutions brought by BPL’s time-critical freight forwarding capabilities further enhances UPS Healthcare solutions for customers in Europe.
For more information about UPS innovations and customer-driven solutions, visit about.ups.com.
About UPS
UPS (NYSE: UPS) is one of the world’s largest companies, with 2023 revenue of $91.0 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 500,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. More information can be found at www.ups.com, about.ups.com and www.investors.ups.com.
About UPS Healthcare
UPS Healthcare delivers unparalleled healthcare logistics expertise to its customers around the world. UPS Healthcare has 17 million square feet of cGMP and GDP-compliant healthcare distribution space globally. Services include inventory management, cold chain packaging and shipping, storage and fulfillment of medical devices and lab and clinical trial logistics. UPS Healthcare's global infrastructure, UPS® Premier visibility service, track and trace technology and global quality system are well-suited to meet today's complex logistics demands for the pharmaceutical, medical device and laboratory diagnostic industries. Visit Healthcare.ups.com for more information.
About Frigo-Trans
Frigo-Trans provides an end-to-end warehouse and transportation solution for pharmaceutical and biotech customers. Frigo-Trans does this by utilizing best-in-class distribution facilities and a pharmacy-focused, Pan-European, cold-chain transportation network. Other value-added services include, but are not limited to, packaging, handling and inventory management. Headquartered in Fußgönheim, Germany, Frigo-Trans’s network expands across all countries in Europe.
About BPL
BPL offers individual transport management for GDP-compliant shipping of time-critical and temperature-sensitive products. BPL manages a high-quality network of air and ocean freight carriers along with customs clearance to meet the complex, cross border needs of customers. BPL prioritizes serving biopharma customers with special temperature, quality and speed requirements. BPL is headquartered in Duesseldorf, Germany.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108660127/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy9.1.2025 09:00:00 CET | Press release
Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted powder of Arachis hypogaea L., semen (peanut)) for thetreatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway). This approval of the extension of indication of Palforzia® to toddlers, follows the July 2024 approval by the U.S. Food and Drug Administration (FDA). Palforzia® is the first and only EMA and FDA approved oral immunotherapy for toddlers with a confirmed diagnosis of peanut allergy. “Peanut allergy is one of the most frequent food allergies. Early intervention is crucial to reduce the risks of accidental exposure and may be very important in improving long-term outcomes. The approval of Palforzia for toddl
Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference9.1.2025 08:37:00 CET | Press release
Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Thursday, January 16, 2025. The company’s presentation will begin at 8:30 a.m. PT/11:30 am (Eastern Time). The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann Pick type C (NPC). Positive topline data reported earlier this year from the company’s successful Phase 2 study investigating nizubaglustat in GM2 and NPC patients demonstrated that the compound had a positive safety profile. Preliminary improvements or stabilization of clinical endpoints were observed in the majority of patients, highlighting encouraging early efficacy trends for the compound. Azafaros is preparing to initiate Phase 3 studies with nizubaglustat in
Kaneka Acquires EndoStream Medical Ltd.9.1.2025 06:21:00 CET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) acquired 96.8% of shares of EndoStream Medical Ltd. (Headquarters: Or Akiva, Israel; CEO: Danel Mayer; hereinafter referred to as ESM), an Israeli medical equipment company, on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus™ device for aneurysm treatment currently under development. We aim to achieve sales of over 20 billion yen by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108226003/en/ Cerebral aneurysm treatment device “Nautilus™” (Graphic: Business Wire) ESM is a manufacturer of innovative technologies in the field of cerebrovascular diseases and is developing a device for the treatment of cerebral aneurysms called “Nautilus™” that can treat aneurysms with wide openings in cerebr
KRAFTON Showcases AI Model ‘CPC’ Built with NVIDIA ACE at CES 20259.1.2025 03:37:00 CET | Press release
Shaping the future of gaming with KRAFTON’s AI technology and NVIDIAHands-on demo features CPC technology applied to the PUBG IP Franchise and inZOI KRAFTON (CEO Changhan ‘CH’ Kim) set a new milestone for the global gaming industry with the introduction of ‘CPC’ (Co-Playable Character), an NPC (Non-Player Character) brought to life with generative AI, in collaboration with NVIDIA, at the world’s largest IT exhibition CES 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108628507/en/ Kangwook Lee, Head of the Deep Learning Division at KRAFTON (Photo: KRAFTON) On January 8, KRAFTON joined NVIDIA at the Fontainebleau Hotel in Las Vegas. KRAFTON showcased an innovative AI experience built with NVIDIA ACE technologies, presenting a bold vision for the future of gaming. Kangwook Lee, Head of the Deep Learning Division at KRAFTON, demonstrated CPC, describing it as “a groundbreaking character concept enabled by an on-device
LR Health & Beauty Celebrates Its 40th Anniversary8.1.2025 15:04:00 CET | Press release
Social Commerce Company has been giving sales partners and customers a better quality of life with high-quality product solutions for four decades The Social Commerce Company LR Health & Beauty is looking back on 40 years of company history this year. The company, which was founded in 1985, has developed into a global player in the direct selling industry in recent years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108836518/en/ LR Headquarters (Photo: Business Wire) LR Health & Beauty has been setting innovative trends in the nutritional supplements and cosmetics sector for 40 years. The unique selling point: The products are sold by independent sales partners who earn an additional income by recommending products and setting up their own business. "LR stands for quality, innovation and a strong people business that offers an attractive business model to people who want more flexibility, more self-fulfilment and finan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom